Johnson & Johnson Announces Senior Leadership Appointments
Vision at Johnson & Johnson has appointed Caroline Blackie, MS, OD, PhD, FAAO, as vice president of medical affairs. Dr. Blackie has been with the company for 8 years and previously served as senior medical director and interim head of medical affairs. The company has also appointed Paul Lisenby as global head of research and development, effective August 4, 2025. Mr. Lisenby brings global expertise, having served as a product development leader for several large medical technology companies.
Dr. Blackie brings experience in direct patient care and scientific research, with a track record of leadership in clinical and medical affairs in the vision industry. Her expertise across vision care and surgical platforms will help guide solutions for the highest unmet medical needs. Mr. Lisenby will be responsible for shaping the global R&D strategy and driving innovation across the Vision portfolio. With a focus on accelerating transformative solutions, he will leverage his track record of cross-functional leadership in new product development to drive the technology pipeline and increase the company’s cadence of launching breakthrough innovations in eye health.
"Caroline’s unwavering commitment to improving the patient and eye care professional experience through medical affairs has been instrumental in our delivery of innovation,” shared Peter Menziuso, group chairman for Vision at Johnson & Johnson. "We are thrilled to welcome Paul back to lead research and development for Vision at Johnson & Johnson. His wealth of experience in leading scientific discovery all the way through to introducing novel solutions will be critical as we build on our legacy of firsts and bring forward the next wave of material and optical innovation.”
“I am honored to lead our medical affairs experts in making an even greater impact for patients who are counting on us,” said Dr. Caroline Blackie, VP of medical affairs for Vision at Johnson & Johnson.
"Vision health is central to global well-being, and I am passionate to help accelerate scientific breakthroughs with unwavering urgency to improve eye health for the millions of patients we serve around the world,” said Paul Lisenby, global head of R&D for Vision at Johnson & Johnson. “I am excited to further fuel the strong momentum this team has created. Together we will push the boundaries of technology and deliver innovations that make a meaningful difference in people’s lives.”